Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 21;166(6):390-400.
doi: 10.7326/M16-1107. Epub 2017 Feb 7.

Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users: A Cross-sectional Study

Affiliations

Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users: A Cross-sectional Study

Lion Shahab et al. Ann Intern Med. .

Abstract

Background: Given the rapid increase in the popularity of e-cigarettes and the paucity of associated longitudinal health-related data, the need to assess the potential risks of long-term use is essential.

Objective: To compare exposure to nicotine, tobacco-related carcinogens, and toxins among smokers of combustible cigarettes only, former smokers with long-term e-cigarette use only, former smokers with long-term nicotine replacement therapy (NRT) use only, long-term dual users of both combustible cigarettes and e-cigarettes, and long-term users of both combustible cigarettes and NRT.

Design: Cross-sectional study.

Setting: United Kingdom.

Participants: The following 5 groups were purposively recruited: combustible cigarette-only users, former smokers with long-term (≥6 months) e-cigarette-only or NRT-only use, and long-term dual combustible cigarette-e-cigarette or combustible cigarette-NRT users (n = 36 to 37 per group; total n = 181).

Measurements: Sociodemographic and smoking characteristics were assessed. Participants provided urine and saliva samples and were analyzed for biomarkers of nicotine, tobacco-specific N-nitrosamines (TSNAs), and volatile organic compounds (VOCs).

Results: After confounders were controlled for, no clear between-group differences in salivary or urinary biomarkers of nicotine intake were found. The e-cigarette-only and NRT-only users had significantly lower metabolite levels for TSNAs (including the carcinogenic metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol [NNAL]) and VOCs (including metabolites of the toxins acrolein; acrylamide; acrylonitrile; 1,3-butadiene; and ethylene oxide) than combustible cigarette-only, dual combustible cigarette-e-cigarette, or dual combustible cigarette-NRT users. The e-cigarette-only users had significantly lower NNAL levels than all other groups. Combustible cigarette-only, dual combustible cigarette-NRT, and dual combustible cigarette-e-cigarette users had largely similar levels of TSNA and VOC metabolites.

Limitation: Cross-sectional design with self-selected sample.

Conclusion: Former smokers with long-term e-cigarette-only or NRT-only use may obtain roughly similar levels of nicotine compared with smokers of combustible cigarettes only, but results varied. Long-term NRT-only and e-cigarette-only use, but not dual use of NRTs or e-cigarettes with combustible cigarettes, is associated with substantially reduced levels of measured carcinogens and toxins relative to smoking only combustible cigarettes.

Primary funding source: Cancer Research UK.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

LS has received an honorarium for a talk, an unrestricted research grant and travel expenses to attend meetings and workshops from Pfizer, a pharmaceutical company that makes smoking cessation products, and has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care companies. MLG reports research grants from and served as an advisory board member to pharmaceutical companies that manufacture smoking cessation medications. JB has received unrestricted research funding from Pfizer to study smoking cessation. RW has received travel funds and hospitality from, and undertaken research and consultancy for, pharmaceutical companies that manufacture or research products aimed at helping smokers to stop. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1. Urinary and salivary nicotine metabolite levels by group^
^Boxplots show median with interquartile range, IQR (25%-75%); error bars show Tukey’s whiskers and cross indicates arithmetic mean (geometric means are provided in Table S1); Solid grey circles show outliers; *Measured in urine: data are raw values divided by ratio of observed to covariate-adjusted creatinine levels; values below the limit of detection (LOD) were imputed by LOD divided by square root of 2; †Measured in saliva; There were no significant differences between groups; NRT – Nicotine replacement therapy; EC – Electronic cigarette; Cig-Cigarette
Figure 2
Figure 2. Urinary metabolite levels^ for selected toxicants by group*: (A) Tobacco- specific N-nitrosamine (NNK), (B) Acrolein, (C) Acrylamide, (D) Acrylonitrile, (E) 1,3-butadiene, (F) Ethylene oxide
^Data are raw values divided by ratio of observed to covariate-adjusted creatinine levels; values below the limit of detection (LOD) were imputed by LOD divided by square root of 2; *Boxplots show median with interquartile range (25%-75%); error bars show Tukey’s whiskers and cross indicates arithmetic mean (geometric means are provided in Table S1); Solid grey circles show outliers; Significant pairwise comparisons are presented in Table S1; NRT – Nicotine replacement therapy; EC – Electronic cigarette; Cig-Cigarette

Comment in

  • E-Cigarettes and Toxin Exposure.
    Aubin HJ, Guénel P, Boutron-Ruault MC, Matrat M, Luquiens A, Dupont P. Aubin HJ, et al. Ann Intern Med. 2017 Oct 3;167(7):524-525. doi: 10.7326/L17-0314. Ann Intern Med. 2017. PMID: 28973203 No abstract available.
  • E-Cigarettes and Toxin Exposure.
    Shahab L, Goniewicz ML, Blount BC, Brown J, West R. Shahab L, et al. Ann Intern Med. 2017 Oct 3;167(7):525-526. doi: 10.7326/L17-0315. Ann Intern Med. 2017. PMID: 28973204 No abstract available.

Similar articles

Cited by

References

    1. Vardavas CI, Filippidis FT, Agaku IT. Determinants and prevalence of e-cigarette use throughout the European Union: a secondary analysis of 26 566 youth and adults from 27 Countries. Tob Control. 2015;24(5):442–8. - PubMed
    1. Hajek P, Etter JF, Benowitz N, Eissenberg T, McRobbie H. Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction. 2014;109(11):1801–10. - PMC - PubMed
    1. Grana R, Benowitz N, Glantz SA. E-cigarettes: a scientific review. Circulation. 2014;129(19):1972–86. - PMC - PubMed
    1. Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014;23(2):133–9. - PMC - PubMed
    1. Jensen RP, Luo W, Pankow JF, Strongin RM, Peyton DH. Hidden formaldehyde in e-cigarette aerosols. N Engl J Med. 2015;372(4):392–4. - PubMed